Clara Barthelemy

Clara Barthelemy

Auto-generated profile, based on publicly available information

Clara Barthelemy

Cells Therapy Unit, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
MAMarie‐Stéphane Aigrot
Marie‐Stéphane Aigrot
CBClara Barthelemy
Clara Barthelemy
SMSarah Moyon
Sarah Moyon
GDGaelle Dufayet‐Chaffaud
Gaelle Dufayet‐Chaffaud
LILeire Izagirre‐Urizar
Leire Izagirre‐Urizar
T Vanja Tepavcevic
Vanja Tepavcevic
Preventing neurodegeneration‐associated disability progression in patients with multiple sclerosis (MS) remains an unmet therapeutic need. As remyelination prevents axonal degeneration, promoting this process in patients might enhance neuroprotection. In demyelinating mouse lesions, local overexpression of semaphorin 3F (Sema3F), an oligodendrocyte progenitor cell (OPC) attractant, increases remyelination. However, molecular targeting to MS lesions is a challenge. A clinically relevant paradigm for delivering Sema3F to demyelinating lesions could be to use blood‐derived macrophages as vehicles. Thus, we chose transplantation of genetically modified hematopoietic stem cells (HSCs) as means of obtaining chimeric mice with circulating Sema3F‐overexpressing monocytes. We demonstrated that Sema3F‐transduced HSCs stimulate OPC migration in a neuropilin 2 (Nrp2, Sema3F receptor)‐dependent fashion, which was conserved in middle‐aged OPCs. While demyelinating lesions induced in mice with Sema3F‐expressing blood cells showed no changes in inflammation and OPC survival, OPC recruitment was enhanced which accelerated the onset of remyelination. Our results provide a proof of concept that blood cells, particularly monocytes/macrophages, can be used to deliver pro‐remyelinating agents “at the right time and place,” suggesting novel means for remyelination‐promoting strategies in MS.

28 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MAMarie-Stephane Aigrot
Marie-Stephane Aigrot
CBClara Barthelemy
Clara Barthelemy
SMSarah Moyon
Sarah Moyon
GDGaelle Dufayet-Chaffaud
Gaelle Dufayet-Chaffaud
LILeire Izagirre-Urizar
Leire Izagirre-Urizar
T Vanja Tepavcevic
Vanja Tepavcevic
Preventing neurodegeneration-associated disability progression in patients with multiple sclerosis (MS) remains an unmet therapeutic need. As remyelination prevents degeneration of demyelinated axons, promoting this process in patients might halt the development of permanent disability. In demyelinating mouse lesions, local overexpression of Semaphorin 3F (Sema3F), an oligodendrocyte progenitor cell (OPC) attractant, increases OPC recruitment and remyelination. However, molecular targeting to MS lesions is a challenge because these are disseminated in the central nervous system. We hypothesized that a clinically-relevant paradigm to deliver Sema3F to demyelinating lesions and increase OPC recruitment may be to use blood-derived macrophages as vehicles. Thus, we chose transplantation of genetically-modified hematopoietic stem cells (HSCs) as means of obtaining circulating monocytes that overexpress Sema3F. We first demonstrated that the supernatant from Sema3F-lentiviral vector transduced HSCs stimulates OPC migration in Neuropilin 2 (Nrp2, Sema3F receptor)-dependent fashion. We then investigated whether OPCs remain responsive to Sema3F with age. While Sema3F expression in the lesions of middle-aged and old mice (characterized by decreased efficiency of OPC recruitment and remyelination) was decreased, middle-aged OPCs retained Nrp2 expression and migrated in response to both recombinant Sema3F and Sema3F-transduced cell supernatant in vitro. We then investigated whether blood cells engineered to overexpress Sema3F can target demyelinating CNS lesions and improve remyelination. Thus, we transplanted Sema3F-transduced HSCs and obtained chimeric mice (with Sema3F overexpression in blood cells), in which we induced demyelinating spinal cord lesions. Transgene-carrying cells, predominantly macrophages, quickly infiltrated lesions in both control and Sema3F chimeras. While infiltration of Sema3F-expressing cells did not alter the inflammatory status of the lesions nor OPC survival, it increased OPC recruitment, which accelerated the onset of remyelination. Our results provide a proof-of-concept that blood cells, particularly monocyte-derived macrophages, can be used to deliver pro-remyelinating agents “at the right time and place”, suggesting novel means for remyelination-promoting strategies.

12 September 2025 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
CBClara. Barthélemy
Clara. Barthélemy
MJMatthieu Jestin
Matthieu Jestin
ABAnne Brignier
Anne Brignier
NPNathalie Parquet
Nathalie Parquet
FCFlorian Chevillon
Florian Chevillon
NDNathalie Dhédin
Nathalie Dhédin